The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of &#945;-Sarcoglycan&#8211;Deficient Muscular Dystrophy by E. Gazzerro et al.
The American Journal of Pathology, Vol. 189, No. 2, February 2019ajp.amjpathol.orgMUSCULOSKELETAL PATHOLOGYThe Danger Signal Extracellular ATP Is Involved
in the Immunomediated Damage of
a-SarcoglycaneDeficient Muscular Dystrophy
Elisabetta Gazzerro,*y Serena Baratto,z Stefania Assereto,* Simona Baldassari,* Chiara Panicucci,z Lizzia Raffaghello,zx
Paolo Scudieri,{ Davide De Battista,k Chiara Fiorillo,* Stefano Volpi,** Linda Chaabane,k Mauro Malnati,k Graziella Messina,yy
Santina Bruzzone,zz Elisabetta Traggiai,xx Fabio Grassi,{{kk*** Carlo Minetti,* and Claudio BrunozFrom the Pediatric Neurology and Muscle Disease Unit,* the Center of Translational and Experimental Myology,z the Stem Cell Laboratory and Cell Therapy
Center,x and the Pediatria II Unit,** IRCCS Istituto Giannina Gaslini, Genova, Italy; the Charité Universität-Experimental and Clinical Research Center,y
Berlin, Germany; the Telethon Institute of Genetics and Medicine,{ Napoli, Italy; the Unit of Human Virology,k Division of Immunology, Transplantation and
Infectious Disease, Ospedale San Raffaele, Milano, Italy; the Departments of Biosciencesyy and Medical Biotechnologies and Translational Medicine,{{
University of Milan, Milan, Italy; the Department of Experimental Medicine,zz University of Genova, Genova, Italy; the Novartis Institute for Research in
Biomedicine,xx Basel, Switzerland; the Institute for Research in Biomedicine,kk Università della Svizzera Italiana, Bellinzona, Switzerland; and the Istituto
Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi”,*** Milan, ItalyAccepted for publicationC
hOctober 16, 2018.
Address correspondence to
Claudio Bruno, M.D., Ph.D.,
Center of Translational and
Experimental Myology, Istituto
Giannina Gaslini, Via G Gaslini,
5, Genova 16147, Italy; or
Elisabetta Gazzerro, M.D.,
Charité Universität-
Experimental and Clinical
Research Center, Lindenberger
Weg 80, Berlin 13125,
Germany. E-mail:
claudiobruno@gaslini.org or
elisabetta.gazzerro@charite.de.opyright ª 2019 American Society for Inve
ttps://doi.org/10.1016/j.ajpath.2018.10.008In muscular dystrophies, muscle membrane fragility results in a tissue-specific increase of danger-
associated molecular pattern molecules (DAMPs) and infiltration of inflammatory cells. The DAMP
extracellular ATP (eATP) released by dying myofibers steadily activates muscle and immune purinergic
receptors exerting dual negative effects: a direct damage linked to altered intracellular calcium
homeostasis in muscle cells and an indirect toxicity through the triggering of the immune response and
inhibition of regulatory T cells. Accordingly, pharmacologic and genetic inhibition of eATP signaling
improves the phenotype in models of chronic inflammatory diseases. In a-sarcoglycanopathy, eATP
effects may be further amplified because a-sarcoglycan extracellular domain binds eATP and displays an
ecto-ATPase activity, thus controlling eATP concentration at the cell surface and attenuating the
magnitude and/or the duration of eATP-induced signals. Herein, we show that in vivo blockade of
the eATP/P2X purinergic pathway by a broad-spectrum P2X receptoreantagonist delayed the pro-
gression of the dystrophic phenotype in a-sarcoglycanenull mice. eATP blockade dampened the
muscular inflammatory response and enhanced the recruitment of forkhead box protein P3epositive
immunosuppressive regulatory CD4þ T cells. The improvement of the inflammatory features was asso-
ciated with increased strength, reduced necrosis, and limited expression of profibrotic factors, sug-
gesting that pharmacologic purinergic antagonism, altering the innate and adaptive immune
component in muscle infiltrates, might provide a therapeutic approach to slow disease progression in a-
sarcoglycanopathy. (Am J Pathol 2019, 189: 354e369; https://doi.org/10.1016/j.ajpath.2018.10.008)Supported by Telethon-Italy grant GEP12053 (C.B.) and Cinque per
mille dell’IRPEFeFinanziamento della ricerca sanitaria, Finanziamento
Ricerca Corrente, Ministero Salute (L.R.).
E.G., S.Bar., and S.A. contributed equally to this work.
Disclosures: None declared.Sarcoglycanopathies represent a subgroup of autosomal
recessive limb-girdle muscular dystrophies (LGMDs) caused
by mutations in one of the four sarcoglycan (SG) genes,
which encode four transmembrane proteins (a-, b-, g-, or d-
SG) organized in a tetrameric structure on the cell surface.1
The clinical phenotype of a-sarcoglycanopathy
(LGMD2D; Online Mendelian Inheritance in Man number
608099) is heterogeneous.2 Progressive degeneration of
skeletal muscle leads to loss of ambulation, respiratorystigative Pathology. Published by Elsevier Incinsufficiency, and often premature death in the early
thirties.3 The rapidity of disease progression and the age of
onset are variable, ranging from severe forms with onset in. All rights reserved.
Extracellular ATP in a-Sarcoglycanopathythe first decade of life and rapid evolution, to milder forms
with later onset and slower progression. Currently, no
treatment is available for these patients.
Sarcoglycans and dystrophin are main components of the
dystrophin-glycoprotein complex, the crucial structural link-
age between the intracellular cytoskeleton and the extracel-
lular matrix that provides stability to the sarcolemma and
offers muscle fibers protection from muscle
contractioneinduced stress. In both sarcoglycanopathies and
dystrophinopathies, dystrophin-glycoprotein complex
disruption leads to a mechanically weaker muscle plasma
membrane that is easily damaged during contraction, allow-
ing release of intracellular molecules, which act as damage-
associated molecular pattern molecules (DAMPs).4 These
self-molecules execute precise intracellular tasks in both
innate and adaptive immunity, exerting disparate functions
when released into the extracellular space. Among DAMPs,
extracellular ATP (eATP) and its derivates are pleiotropic
regulators of cell function.5 In muscle, the primary function of
ATP is energy transfer; however, after cell damage, it is
quickly released in the extracellular space, where it acts as
DAMP. Once in the extracellular space, eATP activates
plasma-membrane nonselective ion channels purinergic P2X
1 to 7 receptors and P2Y 1, 2, 4, 6, and 11 to 14, guanine
nucleotide binding protein-coupled receptors.6,7 The role of
eATP and P2X purinergic signal on mdx dystropathology has
been recently well established. We have shown that blockade
of eATP/P2X purinergic signaling by periodate-oxidase ATP
(oATP) delayed the progression of the dystrophic phenotype,
dampening the local inflammatory response in dystrophin-
deficient mdx mice.8 These results are in agreement with
the phenotype displayed by mdx/P2X7 double-knockout
mice, which showed a reduction of the inflammatory and
fibrotic response in skeletal muscles and heart.9
We hypothesized that the role of eATP may be equally
relevant in a-SG deficiency because this protein displays in
its extracellular domain an ecto-ATPase activity, which al-
lows conversion of ATP to the inactive form ADP.10,11
Herein, we provide the first set of evidences of a patho-
genetic role of eATP in a-sarcoglycanopathy. Short-term
pharmacologic inhibition of eATP signaling improved
muscular function and morphology, inhibited the effector
adaptive and the innate immune response, reduced the
expression of profibrotic factors, and enhanced forkhead
box protein P3epositive (Foxp3þ) CD4þ T-regulatory cell
muscle infiltration in a-sarcoglycan (Sgca) mice. It is thus
feasible that a-SG deficiency can amplify the magnitude of
eATP-induced signals, worsening the immunomediated
damage in LGMD2D patients.
Materials and Methods
In Vivo Treatment with oATP
Sgca knockout mice [kindly donated by Prof. Giulio Cossu
(University of Manchester, Manchester UK)] were treatedThe American Journal of Pathology - ajp.amjpathol.orgwith oATP at 6 mmol/L or phosphate-buffered saline (PBS)
alone daily for 4 weeks by i.p. injection and were sacrificed
at the end of treatment by carbon dioxide inhalation. A
group of age-matched wild-type (WT) C57Bl/6J male mice
was used as internal control. The experiment was repeated
in two separate 4-week trials, which both included 5 to 7
mice in each experimental group. Thus, the results are
indicative of at least 10 animals per group. The Sgca mice
were randomly assigned to the experimental groups, and the
testing of samples was performed blindly (S.A. and S.Bal.).
Blood samples were collected by intracardial puncture at
the end of the fourth week of treatment and centrifuged for
10 minutes at 7000  g. Immediately after centrifugation,
the serum was isolated and stored at 20C. Serum creatine
kinase levels were measured using the creatine kinasee
N-acetyl cysteine quantitative system, according to manu-
facturer’s instructions (BPC BioSED, Rome, Italy).
All animal experiments were performed in accordance
with the Swiss Federal Veterinary Office guidelines and
authorized by the Animal Studies Committee of Cantonal
Veterinary.
Four-Limb Hanging Test
At the beginning of the study and at the end of the second and
fourth week of treatment, the muscle strength of oATP-
treated, PBS-treated Sgca, and WT control mice was scored
through the four-limb hanging test. In this method, mice are
subjected to a 180-second lasting hanging test, duringwhich a
falling score is recorded. In each of the two treatments, all of
themice had to hang for three trials, and the averagemaximum
hanging time of the three trials was measured (standard
operating procedure, http://www.treat-nmd.eu/research/
preclinical/preclinical-efficacy-standards, last accessed
December 1, 2017).
Reagents and Antibodies
oATP (Sigma-Aldrich, St. Louis, MO) was reconstituted at
a final concentration of 100 mmol/L in PBS and stored at
80C; the reconstituted drug was thawed and diluted in
PBS at 6 mmol/L immediately before use. Lipopolysac-
charide (LPS; Sigma-Aldrich) was reconstituted at a final
concentration of 1 mg/mL in Hanks’ balanced salt solution
and stored at 20C, ATP (Sigma-Aldrich) was recon-
stituted at 100 mmol/L (pH 7) in water with sodium hy-
droxide and stored at 20C, and benzoyl ATP (BzATP;
Sigma-Aldrich) was reconstituted at 10 mmol/L in water
and stored at 20C.
The antibodies and dilutions used in the study include the
following: mouse monoclonal antibody to collagen type I
[1:500 for Western blot (WB) analysis] and rat monoclonal
antibody to Ly6C [1:500 for immunohistochemistry (IHC)]
from Abcam (Cambridge, UK); rat monoclonal antibody to
CD45 (1:10 for IHC) from BD Pharmigen (San Jose, CA);
mouse monoclonal antibody to activating signal355
Gazzerro et alcointegratore1 (ASC-1) (1:500 for WB analysis) and rabbit
polyclonal antibodies to glyceraldehyde phosphate dehy-
drogenase (1:500 for WB analysis) from Santa Cruz
Biotechnology (Dallas, TX); rabbit polyclonal antibody to
CD3 (1:20 for IHC); rabbit polyclonal antibodies to P2X7
receptor (R; extracellular) and P2X4R (1:50 and 1:300,
respectively, for immunofluorescence) from Alomone Labs
(Jerusalem, Israel); rabbit polyclonal antibody to trans-
forming growth factor (TGF)-b (1:1000 for WB analysis)
from Cell Signaling Technology (Danvers, MA); mouse
monoclonal antibody to CD39 (1:1000) from Abcam;
mouse monoclonal antibody to a-SG (1:100 for WB anal-
ysis) from Novocastra (Newcastle upon Tyne, UK); mouse
monoclonal antibody to b-dystroglycan (1:50 for WB
analysis) from Novocastra; mouse monoclonal antie
caveolin-3 (1:10,000 for WB analysis) from BD Bioscience
(Milan, Italy); mouse monoclonal antibody to myosin heavy
chain (fast; 1:1000 for WB analysis) from Novocastra;
rabbit anti-mouse IgG horseradish peroxidaseeconjugated
(1:700 for WB analysis) antibodies from Dako (Glostrup,
Denmark); donkey anti-rabbit IgG horseradish
peroxidaseeconjugated (1:5000 for WB analysis) anti-
bodies from GE Health Care (Little Chalfont, UK); mouse
monoclonal anti-rat k and l light chain horseradish
peroxidaseeconjugated (1:100 for IHC) antibody from
Sigma-Aldrich; rat monoclonal to FOXP3 (1:20 for IHC)
from eBioscience (Waltham, MA); and goat anti-mouse
AlexaFluor 488 and donkey anti-rat AlexaFluor 594 (1:750
for immunofluorescence) antibodies from Thermo Fisher
Scientific (Waltham, MA). The EnVision Detection System
Peroxidase/Diaminobenzidine, rabbit and mouse, was from
Dako. The Annexin A5-FITC/7-AAD Kit was purchased
from Beckman Coulter (Marseille, France).
Satellite Cell Isolation from Total Muscle
Satellite cells were isolated from WT and Sgca mice at
passage 8 to passage 10. Forelimb, hind limb, and dia-
phragm muscles were dissected, mechanically cut, and
enzymatically digested at 37C under constant shaking with
a solution containing collagenase I (100 mg/mL; Sigma-
Aldrich), dispase (500 mg/mL; Gibco, Waltham, MA), and
DNaseI (100 mg/mL; Roche, Basel, Switzerland) in PBS
(Sigma-Aldrich). Undigested tissue was precipitated for 5
minutes, and the supernatant was centrifuged for 5 minutes
at 1200  g. The cell pellet was resuspended in Dulbecco’s
modified Eagle’s medium plus 10% fetal bovine serum, 1%
L-glutamine, 1% penicillin/streptomycin, and 1% genta-
micin; then, it was preplated in 150-mm Petri uncoated
dishes for 1 hour. After preplating, the nonadherent satellite
celleenriched population was collected and plated in
collagen-coated (collagen from calf skin; Sigma-Aldrich)
90-mm Petri dishes at a density of 30,000 cells per Petri
dish. After a few days in proliferation, the myoblasts were
eventually plated at high density in differentiation medium
(Dulbecco’s modified Eagle’s medium, 10% donor horse356serum, 1% L-glutamine, 1% penicillin/streptomycin, 1%
gentamicin, and 2.5 ng/mL basic fibroblast growth factor).
Histologic Studies
Sections (7 mm thick) from gastrocnemii (GN) and anterior
tibialis muscles isolated from PBS-treated mice, oATP-Sgca
mice, and WT controls were cut on a cryostat and stained
with standard hematoxylin and eosin and acid phosphatase
for inflammatory reactions and Masson trichrome stain.
Image analysis in termsof area fraction quantification, signal
intensity, and object counting was performed using semi-
automated measurement tools in NIS-Elements AR software
version 4.20.00 (Laboratory Imaging, s.r.o., Prague, Czech
Republic). Central nucleation (expressed as percentage of the
total nuclei in each section) was quantified in a blindedmanner
(S.A. and S.Bal.) in three sections for each muscle (n Z 10
mice for each experimental group, nZ 400 to 600 myofibers
per single animal) with the Axioplan Imager M2 microscope
software AxioVs40 version 4.8.2.0 (Zeiss, Oberkochen, Ger-
many). Paraffin-embedded diaphragms isolated from PBS-
treated oATP-Sgca and WT control mice were cut in cross
section at the midbelly of the muscle (7 mm thick). After
deparaffinization, the slideswere stainedwith hematoxylin and
eosin12 and Picrosirius red staining for collagen fibers.
Immunohistochemistry
Cryosections (5 mm thick) of GN and anterior tibialis
muscles isolated from PBS-treated, oATP-Sgca, and WT
control mice were fixed in acetone at 20C for 10 minutes,
washed three times in PBS, and then washed twice in
0.025% PBS/Triton. Sections were incubated in 8% bovine
serum albumin in PBS (blocking solution) for 1 hour at
room temperature. Then, sections were incubated with pri-
mary antibodies diluted in 1% bovine serum albumin in
PBS solution overnight at 4C. The next day, sections were
washed two times with 0.025% Triton in PBS, incubated 15
minutes in 0.3% H2O2 in PBS, and subsequently incubated
with an Envision secondary antibody for 1 hour. After being
rinsed two times with PBS (5 minutes each), the sections
were stained with a diaminobenzidine substrate solution
(freshly made just before use), counterstained with hema-
toxylin, washed with deionized water, dehydrated through
five changes of alcohol (70%, 90%, 95%, 100%, and 100%)
for 1 minute each, cleared in two changes of xylene
(3 minutes each), and mounted with a Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). Slides
were observed under a Leica Diaplan microscope (Leica,
Wetzlar, Germany). The number of positive cells was
blindly counted (S.Bar. and S.A.) on the whole sections per
mouse. The total area of the section was measured and
expressed in arbitrary units.
For immunofluorescence, unfixed cryosections (5 mm
thick) of GN and anterior tibialis muscles were incubated in
common antibody diluent (BioGenex, San Ramon, CA) forajp.amjpathol.org - The American Journal of Pathology
Table 1 List of Primers Used in This Study
Name Accession number Primer sequence
mPTPRC-F NM_001111316.2 50-ATCTATCCCGCCCAGAATGG-30
mPTPRC-R NM_001111316.2 50-TGCTGTCTTCCTGGGCTTTA-30
mADGRE-1-F NM_010130.4 50-CCCCAGTGTCCTTACAGAGTG-30
mADGRE-1-R NM_010130.4 50-GTGCCCAGAGTGGATGTCT-30
mEGR2-F NM_010118 50-GGACCCAGGTCTCATTCCTA-30
mEGR2-R NM_010118 50-GAGTCCAGAGGACAGGGAAA-30
mCD3e-F NM_007648.4 50-AAGCCTGTGACCCGAGGAAC-30
mCD3e-R NM_007648.4 50-CTGGGTTGGGAACAGGTGGT-30
mCD4-F NM_013488.2 50-GACAGTGTTCCTGGCTTGCG-30
mCD4-R NM_013488.2 50-GCACCTGACACAGCAGAGGA-30
mCD8a-F NM_001081110.2 50-ATGGCTTCATCCCACAACAAG-30
mCD8a-R NM_001081110.2 50-CGTGTCCCTCATGGCAGAA-30
mFOXP3-F NM_001199347 50-CAGTCAAAGAGCCCTCACAA-30
mFOXP3-R NM_001199347 50-AAGGCAGGCTCTTCATGTTT-30
mAREG-F NM_009704 50-AAGGAGGCTTCGACAAGAAA-30
mAREG-R NM_009704 50-TTTACCCTGCATTGTCCTCA-30
mIL10-F NM_010548 50-CCCAGAAATCAAGGAGCATT-30
mIL10-R NM_010548 50-TCACTCTTCACCTGCTCCAC-30
mMYOG-F NM_031189 50- AGTGAATGCAACTCCCACAG-30
mMYOG-R NM_031189 50-CTGTCCACGATGGACGTAAG-30
mSPP1-F NM_001204201 50-TGACGATGATGATGACGATG-30
mSPP1-R NM_001204201 50-GGGACGATTGGAGTGAAAGT-30
mIFNg-F NM_008337 50-TCCTTTGGACCCTCTGACTT-30
mIFNg-R NM_008337 50-GTAACAGCCAGAAACAGCCA-30
mIL6-F NM_001314054 50-CTGGAGCCCACCAAGAACGA-30
mIL6-R NM_001314054 50-TGTGAAGTCTCCTCTCCGGACT-30
mCTGF-F NM_010217 50-GAGTGTGCACTGCCAAAGAT-30
mCTGF-R NM_010217 50-GGCAAGTGCATTGGTATTTG-30
mTGFb1-F NM_011577 50-CCCTATATTTGGAGCCTGGA-30
mTGFb1-R NM_011577 50-CTTGCGACCCACGTAGTAGA-30
mGAPDH-F NM_008084 50-AACTTTGGCATTGTGGAAGG-30
mGAPDH-R NM_008084 50-CCATCCACAGTCTTCTGGGT-30
mPPIA-F NM_008907 50-TCCTGGCATCTTGTCCATGG-30
mPPIA-R NM_008907 50-TTCAGTCTTGGCAGTGCAGA-30
mRPL13a-F NM_009438 50-TCCGATAGTGCATCTTGGCC-30
mRPL13a-R NM_009438 50-AAGTACCAGGCAGTGACAGC-30
Accession numbers from https://www.ncbi.nlm.nih.gov/pubmed/Nucleotide.
F, forward; R, reverse.
Extracellular ATP in a-Sarcoglycanopathy10 minutes and after with primary antibodies (CD45, P2X4,
and P2X7 antibodies) overnight at 4C. After three washes
with PBS, sections were incubated with fluorescent secondary
antibodies in common antibody diluent for 1 hour at roomTable 2 List of Primer/Probe Sets Used in This Study
Probe Catalog number
mP2RX1 Mm00435460_m1
mP2RX2 Mm01202368_g1
mP2RX3 Mm00523699_m1
mP2RX4 Mm00501787_m1
mP2RX5 Mm00473677_m1
mP2RX6 Mm00440591_m1
mP2RX7 Mm00440578_m1
mIL1b Mm00434228_m1
mGAPDH 4352932E
mACTA1 Mm00808218_g1
The American Journal of Pathology - ajp.amjpathol.orgtemperature in the dark. After being washed three times with
PBS, sections were mounted with Vectashield mounting
medium with DAPI (Vector Laboratories). Images were ob-
tained using a Leica SPE confocal microscope equipped with
argon/He-Ne laser sources and an HCX PL APO CS
63.0  1.40 oil objective. During image acquisition, the 488
and 594 lasers were set at 20% energy, and the emission
range was between 500 and 550 and between 650 and 700 nm
for P2X 488 and CD45 594, respectively. The photomultiplier
voltage gain was set to eliminate cell autofluorescence.
Single-plane images were taken at the center of cell thickness.
Real-Time Quantitative PCR
Total RNA was extracted from GN muscles (from 20 to 55
mg) isolated from PBS-treated mice, oATP-Sgca mice, and
WT controls, according to the manufacturer’s protocol357
Figure 1 Inflammatory response and T-regulatory cell (Treg) activation in Sgca mice. Total RNA isolated from the gastrocnemii of 10 Sgca and 7 age- and
sex-matched WT mice was reverse transcribed. The pattern of expression of molecular markers of innate [receptor-type tyrosine-protein phosphatase C (PTPRC),
adhesion G-proteinecoupled receptor E1 (ADGRE1), and early growth response protein 2 (EGR2)] and adaptive [CD3, CD4, and T-cell surface glycoprotein CD8 a
chain (CD8A)] immunity, of Treg activation [forkhead box protein P3 (FOXP3), amphiregulin (AREG), and IL-10)], and of proinflammatory cytokines [interferon
(IFN)-g, IL-1b, and IL-6] was determined by real-time quantitative PCR. PPIA and RPL13A transcript levels were used as housekeeping genes. Data are
expressed as medians  first and third quartiles. PTPRC: WT Z 0.11 (0.05 to 0.18), Sgca Z 0.82 (0.39 to 1.05). ADGRE1: WT Z 0.21 (0.09 to 0.24),
SgcaZ 0.85 (0.43 to 0.96). EGR2: WTZ 0.05 (0.01 to 0.32), SgcaZ 0.59 (0.29 to 1.02). CD3: WTZ 0.25 (0.02 to 0.52), SgcaZ 0.89 (0.06 to 1.36). CD4:
WT Z 0.06 (0.06 to 0.11), Sgca Z 0.63 (0.44 to 1.05). CD8A: WT Z 0.09 (0.04 to 0.17), Sgca Z 0.06 (0.04 to 0.11). FOXP3: WT Z 0.31 (0.30 to 0.31),
SgcaZ 0.43 (0.41 to 0.57). AREG: WTZ 0.001 (0.001 to 0.17), SgcaZ 0.40 (0.07 to 0.57). IL-10: WTZ 0.02 (0.01 to 0.05), SgcaZ 1.00 (0.39 to 1.18).
IL-1b: WT Z 0.02 (0.062 to 0.21), Sgca Z 0.38 (0.31 to 1.05). IL-6: WT Z 0.37 (0.22 to 0.489), Sgca Z 0.67 (0.52 to 0.86). IFN-g: WT Z 0.06 (0.0 to
0.27), Sgca Z 0.66 (0.49 to 1.24). Statistical analysis was performed using the U-test. *P < 0.05, **P < 0.01, and ***P < 0.001.
Gazzerro et al(DNase treatment). Quality and quantity of RNA were
analyzed using a NanoDrop spectrophotometer (NanoDrop
Technologes, Inc., Wilmington, DE).
The cDNA was synthesized from 350 ng of total RNA
with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA). Each RNA sample was controlled for
genomic DNA contamination without reverse transcriptase
addition into a cDNA synthesis mixture. For receptor-type
tyrosine-protein phosphatase C (CD45), adhesion G-proteine
coupled receptor E1 (F4/80), early growth response protein 2,
CD3 ε chain, CD4, CD8 a chain, interferon-g (IFN-g), IL-6,
FOXP3, IL-10, amphiregulin, myogenin, osteopontin358(secreted phosphorylated protein 1), connective tissue growth
factor, and TGF-b1 transcript quantification, real-time
quantitative PCR (qPCR) was performed in triplicate with
the 2 Sso Fast EvaGreen Supermix in the CFX96 Real-
Time PCR Detection System (Bio-Rad Laboratories). Spe-
cific primers for the mouse genes were designed through
Beacon Designer software version 2.0 (Premier Biosoft
International, Palo Alto, CA) and are listed in Table 1.
Briefly, the 15-mL PCR mixture contained diluted cDNA
that corresponded to 8.75 ng of total RNA and 0.2 mmol/L
of each primer. Relative expression levels were normalized
using the comparative Ct (DDCt) method with twoajp.amjpathol.org - The American Journal of Pathology
Figure 2 Sgca myoblasts display a decreased ecto-ATPase activity and undergo apoptosis on treatment with ATP or benzoyl ATP (BzATP). A: Total protein
lysates, isolated from primary myotubes from Sgca and WT age-matched controls, were subjected to Western blot analysis. Membranes were probed with a
mouse monoclonal antiea-SG, b-dystroglycan (b-DG), antiecaveolin-3 (Cav-3), and myosin heavy chain (MyHC) antibody. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was used as a loading control. Samples were run in triplicate. Representative images are shown. B: Primary myotubes isolated from Sgca
and WT mice were cultured in basal medium containing ATP at 0.3 mmol/L. At subsequent times (0, 5, and 15 minutes), 100-mL aliquots of the incubations
were withdrawn and ATP degradation was determined by the phosphate high-performance liquid chromatography analysis. C: Total protein lysates, isolated
from primary myotubes from Sgca and WT age-matched controls, were subjected to Western blot analysis. Membranes were probed with a mouse monoclonal
anti-CD39 antibody. GAPDH was used as a loading control. Samples were run in triplicate. Representative images are shown. D: Primary myotubes isolated from
Sgca mice were pretreated with 1 mg/mL lipopolysaccharide (LPS) for 4 hours and then incubated with 3 mmol/L ATP and 300 mmol/L BzATP for 16 hours. The
cells were stained with the Annexin A5 FITC/7-AAD Kit, and apoptosis was evaluated by flow cytometry. Data are expressed as medians  first and third
quartiles (B); statistical analysis was performed using the U-test. Data are expressed as percentage of apoptotic cells (Annexinþ7-AAD- þ Annexinþ7-AADþ;
D). One representative experiment of three performed is shown. n Z 4 wells per genotype (B). *P < 0.05.
Extracellular ATP in a-Sarcoglycanopathyhousekeeping genes (peptidylprolyl isomerase A and ribo-
somal protein L 13a) by the Bio-Rad CFX Maestro software
1.0 version 4.0.2325.0418. For each specific primer set, the
efficiency was >95% and a single product was seen on the
melting curve analysis.
For mouse P2X receptors and IL-1b quantification, qPCR
was performed in triplicate with the 2 Sso Fast Probes
Supermix (Bio-Rad Laboratories) in a CFX96 Real-Time
PCR Detection System. The 15-mL PCR mixture contained
diluted cDNA that corresponded to 12.5 ng of total RNA,
and premixed primer/probe sets were ordered from Applied
Biosystems (Foster City, CA) (Table 2). Relative expression
levels were normalized using the comparative Ct (DDCt)
method with the housekeeping gene Gapdh and actin-a 1
(Acta1, a muscle specific gene, NM_001272041.1), by the
Bio-Rad CFX Maestro software.The American Journal of Pathology - ajp.amjpathol.orgWestern Blot Analysis
Total protein lysates were isolated from PBS-treated
mice, oATP-Sgca mice, and WT GN muscles, as previ-
ously described.8 Equal amounts of protein (40 to 120 mg)
were resolved in 8% to 15% SDS-PAGE gel and trans-
ferred onto polyvinylidene difluoride membranes
(Immobilon PVDF, Billerica, MA). Membranes were
blocked with 5% bovine serum albumin in PBS/0.1%
Tween 20. Blots were then incubated overnight at 4C
with primary antibodies. Horseradish peroxidase anti-IgG
was used to visualize bound primary antibodies with the
chemiluminescence system (Bio-Rad Laboratories). Band
intensities were evaluated by densitometry using the
Alliance Mini HD9 AutoAutomatic system (Uvitec,
Cambridge, UK).359
Figure 3 P2X4 and P2X7 purinergic receptors are
significantly up-regulated in Sgca muscle tissue. Total
RNA isolated from the gastrocnemii of 10 Sgca and 7
age- and sex-matched WT mice was reverse tran-
scribed. The pattern of expression of P2X receptors
(Rs) was determined by real-time quantitative PCR.
P2X2R transcript levels were not measurable. P2X4R
and P2X7R transcripts are significantly up-regulated in
a-SGedeficient mice. Gapdh and Acta1 were used as
housekeeping genes. Data are expressed as
medians  first and third quartiles. P2X4: WTZ 0.147
(0.140 to 0.249), Sgca Z 0.907 (0.549 to 1.905).
P2X7: WT Z 0.217 (0.167 to 0.258), Sgca Z 0.767
(0.362 to 1.630). Statistical analysis was performed
using the U-test. *P < 0.05.
Gazzerro et alEcto-ATPase Activity
Satellite cells were seeded in 24-well plates (5.5  104 cells/
well) and cultured until they completely differentiated into
mature myotubes. After removal of the culture medium, cells
were washed once with 1 mL Hanks’ balanced salt solution,
and 0.35 mL Hanks’ balanced salt solution containing 0.3
mmol/L ATP was added. At various times (0, 5, and 15 mi-
nutes), 100-l aliquots of the incubations were withdrawn and
incubations were stopped by filtration with a multiscreen vac-
uummanifoldusing Immobilon-Pmembraneplates (Millipore,
Bedford, MA). ATP degradation was determined by the
phosphate high-performance liquid chromatography analysis,
as previously described.13Cellswere lysed, and protein content
in each well was determined by Bradford assay.Apoptosis
Satellite cells were seeded in 24-well plates (6  104 cells/
well) and cultured until they completely differentiated into
mature myotubes. The cells were pretreated with LPS
(1 mg/mL) for 4 hours and then incubated with 3 mmol/L
ATP and 300 mmol/L BzATP for 16 hours. Then, myotubes
were analyzed by flow cytometry, according to other studies
that have adopted the same technique.14e16 Specifically, the
cells were stained with the Annexin A5 FITC/7-AAD Kit,
and apoptosis was evaluated by flow cytometry, according
to the manufacturer’s instructions. Sample analysis was360performed using a Gallios cytometer (Beckman-Coulter)
and Kaluza software version 1.1 (Beckman-Coulter).
Statistical Analysis
Most of the analyzed variables were not normally distributed,
as confirmed by the Shapiro-Wilk test, and therefore differ-
ences of quantitative parameters between two groups of mice
were analyzed by the U-MannWhitney test for nonparametric
data. P< 0.05was considered statistically significant. Data are
expressed asmedians first and third quartiles, as described in
Results and figure legends. Statistica software version 9.1
(StatSoft Co, Tulsa, OK) was used for all of the statistical an-
alyses. Graphs were generated with Graph Pad Prism software
version 6.0 (Graph Pad Software, San Diego, CA).
Results
Sgca Skeletal Muscle Displays an Increased Expression
of Markers of Innate and Adaptive Immunity
To quantify the inflammatory response in muscles isolated
from Sgca mice, the transcript levels of different immune
cell markers and of distinct cytokines were analyzed,
compared with muscles isolated from age-matched WT
mice. a-SGedeficient muscle overexpressed leukocytes as
well as macrophage surface proteins. Receptor-type tyrosine-
protein phosphatase C (CD45), adhesion G-proteinecoupled
receptor E1 (F4/80), and early growth response protein 2ajp.amjpathol.org - The American Journal of Pathology
Figure 4 P2X7R is overexpressed in Sgca muscle cells, whereas P2X4R is mainly expressed in CD45þ cells. A: Frozen muscle tissue sections of gastrocnemii
(GN) from Sgca and WT mice were immunostained with a monoclonal anti-CD45 antibody (red) and a monoclonal P2X7R antibody (red). Representative images are
shown. White arrows indicate examples of the positive cells for P2X7R. B: Frozen muscle tissue sections of GN from Sgca and WT mice were immunostained with a
monoclonal anti-CD45 antibody (red) and a monoclonal P2X4R antibody (red). Representative images are shown. Yellow arrows indicate examples of the positive
cells for P2X4R and CD45. n Z 4 (A and B, Sgca and WT mice). Scale bar Z 25 mm (A and B). Original magnification, 40 (A and B).
Extracellular ATP in a-Sarcoglycanopathywere up-regulated by 7.5-, 4.1-, and 10-fold, respectively.17
CD3 transcripts were increased by 3-fold, with a 10 fold-
increase of the proportion of CD4-expressing lymphocytes,
and a 30% reduction in CD8AmRNA levels. Moreover, CD4
induction was associated with a 1.8-fold up-regulation of
FOXP3, a marker of CD4þ T-regulatory (Treg) cells.
The recruitment of immune cells in the muscle of Sgca mice
was confirmed by a 4.7-, 1.8-, and 11-fold induction of the
proinflammatory cytokines IL-1b, IFN-g, and IL-6, respec-
tively, but also by a 50- and 3-fold induction of the Treg-specificThe American Journal of Pathology - ajp.amjpathol.organti-inflammatory cytokine IL-10 and of the Treg-secreted
growth factor amphiregulin, respectively (Figure 1).
Sgca Primary Myotubes Are Characterized by a Defect
in Ecto-ATPase Activity and Undergo Apoptosis on ATP
Treatment
Primary satellite cells were isolated from the forelimb, hind
limb, and diaphragm muscles of passage 8 to passage 10 old
Sgca and WT mice and cultured until they completely361
Figure 5 oATP improvesmuscle strength and ameliorates creatine kinase
(CK) serum levels in Sgca mice. A: Four-limb hanging test was performed on
PBS-Sgca (light gray line), oATP-Sgca (dark gray line), and age-matchedWT
controls (black line) at the beginning and at the end of the second and
fourth week of treatment. B: Serum CK levels were evaluated at the end of the
fourth week of treatment. Blood samples were obtained via cardiac puncture
from PBS-Sgca, oATP-Sgca, and WT mice. Data are expressed as
medians  first and third quartiles. WT Z 675 (130 to 1220), PBS-
Sgca Z 8460 (3835 to 24,635), oATP-Sgca Z 5360 (3500 to 5440). Sta-
tistical analysis was performed using the U-test. Data are expressed as
means SD (A). nZ 12 animals (A); nZ 10 animals for each experimental
group (B). *P < 0.05 for oATP-treated mice versus PBS-treated mice.
Gazzerro et aldifferentiated into mature myotubes. The absence of expres-
sion of a-SG was confirmed by Western blot analysis on total
cellular extracts. Sgca-deficient cells displayed normal levels
of caveolin-3 and myosin heavy chain, thus indicating the
achievement of a functional muscle cell phenotype. The
decrease observed in b-dystroglycan levels is in accordance
with the disruption of the dystrophin-glycoprotein complex in
a-sarcoglycanopathies (Figure 2A).
The ecto-ATPase activity was quantified bymeasuring ATP
metabolism in mass spectrometry, in WT and Sgca cells
switched to a basal medium containing ATP at 0.3 mmol/L.
When comparedwith theWT, Sgca cells were characterized by
decreased ecto-ATPase activity (Figure 2B), resulting in
increased ATP levels in culture medium. Muscle cells express
the ecto-ATPase CD39, which converts ATP to ADP. How-
ever, the increase in ATP levels observed in the Sgca group
appeared to be specifically related to the absence of the a-SG
ecto-ATPase activity because the protein levels of CD39 were
not modified between Sgca and WT muscle lysates
(Figure 2C).362For the evaluation of apoptosis, the cells were pretreated
with 1 mg/mL LPS for 4 hours, incubated with 3 mmol/L
ATP and 300 mmol/L BzATP for 16 hours, and then stained
with the Annexin A5 FITC/7-AAD Kit. The feasibility of a
citofluorimetric assay in myotubes has been previously
determined.14e16 The number of apoptotic muscle cells was
determined measuring the percentage of Annexin Vþ/7-
AAD and Annexin Vþ/7-AADþ cells (early and late
apoptosis, respectively). The pretreatment with LPS is
supported by the observation that LPS caused a marked up-
regulation of striatal P2X7 expression.18 ATP and, more
potently, BzATP induced apoptosis, an effect that was
further enhanced by a pretreatment with LPS (Figure 2D).
P2XR Is Expressed in Sgca Muscle Tissue
The pattern of expression of the P2XR was evaluated in
muscle lysates from the GN of Sgca mice and age-matched
WT controls. A specific up-regulation of P2X4R and
P2X7R transcripts (sixfold and fourfold, respectively) was
observed (Figure 3), whereas P2X2R transcript levels were
not measurable (Figure 3). To determine whether P2X4R
and P2XR7 were expressed in myofibers or in infiltrating
inflammatory cells, a coimmunostaining was completed
with the pan-granulocyte marker C45 and P2X4 and P2X7R
antibodies, respectively, in GN sections.
P2X4R was hardly detectable on the muscle cell mem-
brane in WT mice, and it was up-regulated and colocalized
with CD45-positive cells in the Sgca mutants (Figure 4A).
P2X7R expression was weak in WT myofibers, whereas
clear and specific P2X7R patches at the plasma membrane
level were detected in Sgca muscle fibers, suggesting an
induction and a higher functionality of the receptor because
of its cell surface localization. This same feature has been
previously shown in the monocytic subset of myeloid-
derived suppressor cells isolated from tumor-bearing
mice19 (Figure 4B).
Targeting P2X Signaling in Vivo Improves Biochemical
and Functional Parameters of Disease Progression in
Sgca Mice
Given the representation of different P2XR in Sgca muscles,
we aimed at initially achieving a pleiotropic antagonistic
effect on eATP signaling cascade. Four-weekeold Sgca
mice were treated with oATP, a compound known to act on
multiple P2X receptor molecules. oATP was administered
via i.p. injections, at the dose of 6 mmol/L. Sgca mice
injected with vehicle alone (PBS) and a group of age- and
sex-matched WT C57Bl/6 mice served as controls. Mice
were weighted at the beginning (baseline) of the treatment
and then on a weekly basis. No significant difference was
detected between the various groups (data not shown). The
evaluation of muscle strength was completed by the four-
limb hanging test at the beginning of the treatment (time 0)
and at the end of the second and fourth weeks of treatment.ajp.amjpathol.org - The American Journal of Pathology
Figure 6 oATP improves the extension of reactive
inflammatory infiltrates and morphologic features in
Sgca mice. A: Frozen muscle tissue sections of gastro-
cnemii (GN) from PBS-Sgca and oATP-Sgca mice were
collected at the fourth week of treatment and stained
with acid phosphatase. Black arrows indicate inflam-
matory infiltrates. Representative images are shown. B:
Graph of the analysis of the fraction areas and intensities
of inflammatory infiltrates/total section area of muscles
represented in A. Data are expressed as medians  first
and third quartiles. Area:WTZ 0.006 (0.002 to 0.0267),
PBS-SgcaZ 0.117 (0.09 to 0.14), oATP-SgcaZ 0.063
(0.04 to 0.09). Signal intensity: WTZ 71,886 (12,400 to
217,000), PBS-SgcaZ 6.30  106 (4.01  106 to 9.12
 106), oATP-SgcaZ 3.85 106 (2.53 106 to 6.13
106). Statistical analysis was performed using theU-test.
C: The number of central nuclei was quantified in 600
fibers of three consecutive fields for each muscle section
stained with hematoxylin and eosin. Data are expressed
as medians first and third quartiles. WTZ 2.00 (1.00
to 3.00), PBS-Sgca Z 82.91 (80.18 to 89.34), oATP-
SgcaZ 70.89 (64.76 to 75.01). Statistical analysis was
performed using the U-test. D: Total RNA isolated from
GN lysates from PBS-Sgca, oATP-Sgca, and WT age-
matched controls was reverse transcribed. Myogenin
transcripts (Myog) were quantified by real-time quanti-
tative PCR. Ppia and Rpl13a served as housekeeping
genes. Data are expressed as medians  first and third
quartiles. WT Z 0.054 (0.037 to 0.076), PBS-
SgcaZ 0.669 (0.19-1.39), oATP-SgcaZ 0.217 (0.10 to
0.55). Statistical analysis was performed using the U-
test. nZ 10 (A, PBS-Sgca and oATP-Sgca mice, C, mice
for each experimental group, and D, PBS-Sgca, oATP-
Sgca, and WT mice). *P < 0.05, **P < 0.01. Original
magnification, 10 (A). AU, arbitrary unit.
Extracellular ATP in a-SarcoglycanopathyAs expected from the literature, the untreated Sgca group
displayed a progressive worsening of muscle strength along
time, whereas the oATP-Sgca cohort maintained the scores
measured at time 0 (P < 0.05 for oATP-treated mice versus
PBS-treated mice after 4 weeks) (Figure 5A).
Serum creatine kinase concentrations, a marker of muscle
cell degeneration, were evaluated at the end of the trial by
cardiac puncture. Creatine kinase was markedly increased in
PBS-Sgca mice when compared with the WT cohort,
whereas the treatment with the P2X antagonist led to a 35%
decrease of this effect (Figure 5B).
Inhibition of P2X Signaling Ameliorates Morphologic
Features and Reduces the Amplitude of the Innate and
Adaptive Immune Responses in Sgca Mice
The fraction area and the intensity of the inflammatory
reactions surrounding degenerative/necrotic muscle cells
were evaluated in GN from PBS- and oATP-treated animals
by acid phosphatase staining, which provides a red positive
signal in activated macrophages and degenerative myo-
fibers. These parameters were decreased in the oATP-treated
group by 46% and 38%, respectively (P < 0.01 and
P < 0.05, respectively) (Figure 6, A and B).The American Journal of Pathology - ajp.amjpathol.orgMuscle morphology was quantified in GN by standard
hematoxylin and eosin staining. Central nucleation (per-
centage), a sign of dystrophic myopathic damage, was
reduced by 14% in GN of oATP-treated animals (Figure 6C).
Moreover, muscle tissue from untreated Sgca mutants, when
compared with WT mice, displayed an increase of myogenin
transcripts, a muscle-specific transcription factor expressed
by committed myoblasts in regeneration and typically up-
regulated in the degenerative/regenerative cell cycles of
active muscular dystrophies. This effect was blunted by 67%
after oATP treatment, thus suggesting an inhibition of
degenerative cellular events (Figure 6D).
In diaphragms, P2X antagonism resulted in a 71% and 11%
decrease in the areas and number of the inflammatory reactions
surrounding the muscle cells in necrosis, respectively (hema-
toxylin and eosin staining). The beneficial effect of purinergic
antagonism was associated also with a 16% reduction of
centralized nuclei (P<0.05) (Supplemental Figure S1).
Immunostaining and measurement of the CD45þ and
Ly6Cþ leukocytes infiltrating the muscle tissue revealed a
positive signal for both markers in different sites of the in-
flammatory responses surrounding necrotic fibers. When
quantified by automated microscopy on the total section
area, the number of CD45þ and Ly6Cþ cells in the total363
Figure 7 oATP induces a decrease of inflammatory cytokines and monocyte infiltration in muscles from Sgca mice. A: Frozen muscle tissue sections of
gastrocnemii (GN) from PBS-Sgca and oATP-Sgca mice were collected at the fourth week of treatment and immunostained with a monoclonal anti-CD45
antibody (red), monoclonal anti-Ly6C antibody (red), and monoclonal antiecaveolin-3 antibody (green). Representative images are shown. White arrow-
heads indicate examples of the positive cells for CD45 and Ly6C markers. B: Graph of the number of CD45þ, Ly6Cþ cells/arbitrary unit (AU) of total section area
of muscles represented in A. Data are expressed as medians  first and third quartiles. CD45: PBS-SgcaZ 8.80 (5.06 to 13.22), oATP-SgcaZ 4.54 (2.51 to
8.18). Ly6C: PBS-SgcaZ 6.02 (4.35 to 11.36), oATP-SgcaZ 4.51 (3.14 to 5.64). Statistical analysis was performed using the U-test. C: Total protein lysates,
isolated from GN of oATP-treated Sgca (oATPþ), untreated Sgca (oATP-), and WT age-matched controls, were subjected to Western blot analysis. Membranes
were probed with a mouse monoclonal antieactivating signal cointegratore1 (ASC-1) antibody. Samples were run in triplicate. Representative images are
shown. n Z 10 (A, PBS-Sgca and oATP-Sgca mice). Original magnification, 20 (A). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Gazzerro et alareas was inhibited by 45% and 25%, respectively, in
oATP-treated mice (Figure 7, A and B).
Accordingly, the protein levels of ASC-1, a coactivator of
NF-kb, were undetectable in WT mice, markedly increased
in Sgca muscle lysates, and significantly inhibited after P2X
blockade (Figure 7C).
The immunostaining and measurement of the CD3 lym-
phocytes infiltrating themuscle tissue showed aCD3-positive
signal in different sites of reactive inflammatory responses.
When quantified by automated microscopy on the total sec-
tion area, the fraction areas of CD3-positive signal were
reduced by 52% in oATP-treated mice (data not shown).
Despite the decrease in the total number of CD3-positive
cells, FOXP3þ cells were increased in muscle tissue of
oATP-treated Sgca mutants by 34% (Figure 8, A and B).364The mechanisms of how oATP affects innate and adap-
tive response in Sgca skeletal muscle were also investigated
by quantification of muscular IL-1b, IL-6, and IFN-g tran-
scripts. When compared with the PBS cohort, these cyto-
kines were reduced by 49%, 39%, and 44%, respectively, in
the oATP group (Figure 8C).
Targeting P2X Signaling in Vivo Decreases Muscular
Fibrotic Degeneration, Reducing the Transcription of
Muscle Profibrotic Factors in Sgca Mice
In accordance with this anti-inflammatory image, P2X
blockade led to a reduction of the transcription of fibrogenic
factors, which ultimately stimulate endomysial fibrosis and
connective replacement of muscle tissue. The transcripts ofajp.amjpathol.org - The American Journal of Pathology
Figure 8 oATP decreases the total number of CD3þ lymphocytes but increases the extension of forkhead box protein P3 (Foxp3)epositive cells in
Sgca mice. A: Frozen muscle tissue sections of gastrocnemii (GN) from PBS-Sgca and oATP-Sgca mice were collected at the fourth week of treatment
and immunostained with a monoclonal anti-FOXP3 antibody. White arrowheads indicate FOXP3þ cells. Representative images are shown. B. Graph of
the number of CD3þ and FOXP3þ cells/arbitrary unit (AU) of total section area of muscles represented in A. Data are expressed as medians  first and
third quartilesPBS-Sgca Z 0.971 (0.72 to 1.07), oATP-Sgca Z 1.308 (1.19 to 1.94). Statistical analysis was performed using the U-test. C: Total RNA
isolated from GN lysates from PBS-Sgca and oATP-Sgca mice was reverse transcribed. IL-1b, IL-6, and interferon (IFN)-g transcripts were quantified by
real-time quantitative PCR. Ppia and Rpl13a served as housekeeping genes. Data are expressed as medians  first and third quartilesIL-1b: PBS-
Sgca Z 0.378 (0.311 to 1.04), oATP-Sgca Z 0.190 (0.13 to 0.49). IL-6: PBS-Sgca Z 0.674 (0.52 to 0.86); oATP-Sgca Z 0.409 (0.28 to 0.54). IFN-g:
PBS-Sgca Z 0.660 (0.49 to 1.23), oATP-Sgca Z 0.367 (0.27 to 0.57). Statistical analysis was performed using the U-test. n Z 10 (A and C, PBS-Sgca
and oATP-Sgca mice). *P < 0.05, **P < 0.01. Original magnification, 20 (A).
Extracellular ATP in a-Sarcoglycanopathyosteopontin (secreted phosphorylated protein 1), connective
tissue growth factor, and TGF-b1 were quantified in total
muscle lysates isolated from the GN of WT, PBS-treated,
and oATP-treated Sgca mice and displayed a 79%, 45%,
and 77% reduction in the presence of eATP blockade,
respectively (Figure 9).
The effects of oATP on collagen type I and on TGF-b
were also confirmed at the protein levels. P2X antagonism
prevented the up-regulation of collagen type I observed in
the untreated cohort, and it led to a reduction of both
dimeric (25 kDa) and monomeric (15 kDa) active TGF-b
isoforms (Figure 10A).
Accordingly, histologic analyses by Masson trichrome
staining on GN sections revealed that oATP treatment led toThe American Journal of Pathology - ajp.amjpathol.orga 20% decrease of the fraction area (Figure 10, B and C).
Staining with Picrosirius red in diaphragms corroborated a
40% and 43% decrease of the fraction area and the intensity
of fibrotic tissue in the oATP-treated group, respectively
(Supplemental Figure S2).Discussion
In sarcoglycanopathies, the mechanically weaker plasma
membrane is easily damaged during muscle contraction,
allowing release of intracellular antigens, infiltration of
immune cells, and induction of profibrotic cytokines and
growth factors.3 Although different experimental models365
Figure 9 oATP induces a decrease of profibrotic factors in muscles from
Sgca mice. Total RNA isolated from gastrocnemii lysates from PBS-Sgca,
oATP-Sgca, and WT age-matched controls was reverse transcribed.
Secreted phosphorylated protein 1 (SPP1), connective tissue growth factor
(CTGF), and transforming growth factor-b (TGF-b) transcripts were
quantified by real-time quantitative PCR. Ppia and Rpl13a served as
housekeeping genes. Data are expressed as medians  first and third
quartiles. SPP1: WT Z 0.015 (0.01 to 0.02); PBS-Sgca Z 0.591 (0.16 to
1.34), oATP-Sgca Z 0.123 (0.11 to 0.32). CTGF: WT Z 0.532 (0.51
to 0.71), PBS-Sgca Z 0.822 (0.74 to 1.62), oATP-Sgca Z 0.452 (0.33
to 0.53). TGF-b: WT Z 0.187 (0.15 to 0.40), PBS-Sgca Z 1.491 (0.36 to
1.82), oATP-Sgca Z 0.339 (0.34 to 0.81). Statistical analysis was per-
formed using the U-test. n Z 10 (PBS-Sgca and oATP-Sgca mice); n Z 5
(WT age-matched controls). *P < 0.05, **P < 0.01.
Gazzerro et alhave shown how distinct anti-inflammatory approaches may
enhance stem cell therapy in mice,20 the molecular mecha-
nisms that trigger the immune-mediated damage in this
disorder have not been described yet. Likewise, limited are
the clinical studies and the clinical experience on anti-
inflammatory strategies in human sarcoglycanopathies.
Conversely, in Duchenne muscular dystrophy, it has been
extensively highlighted that the immune system exerts a
dichotomous role because two types of inflammation that
promote and repair muscle injury are activated in the muscle366tissue.21e25 Type 1 inflammation is characterized by increased
expression of IFN-g and is counterregulated by type 2 cyto-
kines, such as IL-4 and IL-13, and the Treg anti-inflammatory
cytokine IL-10.
Herein, it was found that type 1 and type 2 inflammation
are activated also in a-SG deficiency. When compared with
WT animals, a-SGedeficient muscle tissue displayed
higher expression levels of proinflammatory cytokines, such
as IL-1b, IFN-g, and IL-6, augmented content of the
proinflammatory molecule ASC-1, and increased infiltration
of CD45 leukocytes, macrophages (innate immunity), and
CD4þ lymphocytes (adaptive immunity). This process was
counteracted by an increase in the number of FOXP3þ
CD4þ Tregs, which also showed an activated phenotype, as
confirmed by induced levels of the cytokine IL-10.
The potential role of the DAMP molecule eATP was next
studied in the development of this tissue-specific immune-
mediated damage, and it was shown, for the first time, that
P2X-purinergic signaling is involved in this pathologic
cascade.
Sgca mice were characterized by an enhanced expression
of P2X4 and P2X7 receptors in muscle tissue, confirming
that SG defects, as dystrophinopathies, result into a puriner-
gic pathway overactivation. Although P2X4R was mainly
up-regulated in CD45þ inflammatory cells infiltrating the
muscle, P2X7R was overexpressed on the plasma membrane
of Sgca muscle fibers. Noteworthy, in dystrophic cells, the
receptor molecules were found to be organized in specific
patches, suggesting in the monocytic subset of myeloid-
derived suppressor cells isolated from tumor-bearing mice.19
An excess of ATP in the extracellular milieu can be
counteracted by the action of the ecto-ATPases CD39 and
CD73, which in subsequential order convert ATP to aden-
osine. However, also, a-SG displays in its C-terminal
domain an ecto-ATPase function, and its absence causes a
more consistent accumulation of ATP in the culture medium
of primary myotubes. In turn, as already shown in distinct
cell systems, an excessive extracellular ATP stimulation is
able to exert a direct toxic effect in muscle cells because it
induces apoptosis.26,27 The molecular basis of the proapo-
ptotic effect can be because of an effect on mitochondrial
metabolism or the association with pannexin molecules and
the formation of a cytolytic pore (ie, a large conductance
channel).
According to these first observations, the pharmacologic
inhibition of purinergic signaling via oATP led to an
improvement of muscular function and structure, a reduc-
tion of the innate/adaptive immune response and fibrosis,
and an increase in FOXP3þ CD4þ Treg muscle infiltration.
In this scenario, it is likely that the oATP-mediated boosting
of Treg muscle infiltration played a role in ameliorating the
Sgca mice phenotype. It has been shown that skeletal
muscle resident Treg, producing IL-10 and expressing Areg,
controls the switch of type 1 to type 2 inflammation in
injured muscle and acts directly on muscle satellite cells,
improving muscle repair.28e30 Noteworthy, myoblastsajp.amjpathol.org - The American Journal of Pathology
Figure 10 oATP induces a decrease of collagen
profibrotic factors in muscles from Sgca mice. A:
Total protein lysates, isolated from gastrocnemii
(GN) of PBS-Sgca, oATP-Sgca, and WT age-matched
controls, were subjected to Western blot analysis.
Membranes were probed with a rabbit polyclonal
anti-collagen type I and a mouse monoclonal anti
etransforming growth factor-b (TGF-b; the 25-kDa
dimer and the 15-kDa monomer) antibody.
Representative images are shown. B: Frozen mus-
cle tissue sections of GN from PBS-Sgca, oATP-
Sgca, and WT age-matched controls were collected
at the fourth week of treatment and stained with a
standard Masson trichrome stain protocol. Repre-
sentative images are shown. C: Graph of the frac-
tion areas of fibrotic blue positive signal/arbitrary
unit (AU) of total section area of muscles repre-
sented in B. Data are expressed as medians  first
and third quartiles. WT Z 0.029 (0.026-0-031),
PBS-Sgca Z 0.077 (0.076 to 0.107), oATP-
Sgca Z 0.061 (0.052 to 0.067). Statistical anal-
ysis was performed using the U-test. n Z 6 (A,
PBS-Sgca, oATP-Sgca, and WT mice); n Z 5 (B,
PBS-Sgca, oATP-Sgca, and WT mice). *P < 0.05 for
WT versus Sgca. Original magnification, 10 (B).
GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase.
Extracellular ATP in a-Sarcoglycanopathyisolated from mdx mice showed an increased cytosolic Ca2þ
ion influx and IL-1b release when stimulated with BzATP,31
thus evoking an active role of skeletal muscle cells in the
inflammatory mechanism through P2X-purinergic signaling.
The assessment of Sgca and LGMD2D primary myoblast
behavior under eATP stimulation and the direct effect of
P2XR inhibition on these cells will be evaluated in our
future studies.
oATP was originally described as an irreversible P2X7R
antagonist32 but was shown later to also block other P2XRs,
such as the P2X4 subtype,33 making this compound a good
candidate for a first proof of principle of our hypothesis in
Sgca mice, in which an up-regulation of both P2X7 and
P2X4 receptors was found. oATP has also demonstrated
promise as a treatment modality in several models of
autoimmune diseases. Successful examples are experimental
models of collagen-induced arthritis, autoimmune diabetes,
allergic encephalitis, autoimmune colitis, and allograft
rejection in cardiac and islet transplantation.33e39 In these
disorders, the compound works as a suppressor of the innate
and adaptive immunity as well as an inductor of Treg
expansion.The American Journal of Pathology - ajp.amjpathol.orgHowever, numerous other P2XR antagonists, more effi-
cient and more specific, have been discovered in the past
few years, especially anti-P2X7R.40e43 CE-224,535 has
been tested in clinical trials for rheumatoid arthritis in
patients with an inadequate response to methotrexate. The
drug was not efficacious, compared with placebo, but
demonstrated an acceptable safety and tolerability profile
(NCT00628095).44,45 The purinergic P2X7 antagonist
AZD9056 was shown to have the potential to improve
symptoms in patients with moderate-to-severe Crohn dis-
ease combined with a beneficial risk profile. AZD9056 was
well tolerated, and no serious adverse events were re-
ported.46 The molecule GSK1482160 has already been
explored as a possible tool to detect neuroinflammation, and
a phase I clinical study in humans is currently undergoing
(NCT00849134).47
Currently, no therapies are available for LGMD2D pa-
tients. Many studies in each of the four sarcoglycan de-
ficiencies demonstrated that viral-mediated gene transfer,
using adeno-associated vectors, can correct the pathologic
signs of the disease in animal models.48e56 However, some
previous a-SG gene transfer experiments revealed the367
Gazzerro et aloccurrence of specific immune response, leading to gener-
ation of a-SGespecific antibody, T-cell infiltration of
treated muscles, and disappearance of the vector. In this
respect, we suggest that P2X-purinergic signal antagonism,
with its double anti-inflammatory effect (inhibition of
innate/adaptive inflammatory response and enhancement of
immune tolerance by Treg expansion), could be associated
with gene transfer therapies for the treatment of LGMD2D
to obtain a more stable a-SG expression.
Moreover, this study is in agreement with recent lines of
research, which emphasize the relevance of DAMPs in
chronic degenerative disorders. Intriguingly, these sophis-
ticated molecules are danger signals important not only for
the inflammatory response but also for tissue repair because
they can orchestrate tissue healing by acting on different
receptors. Thus, better understanding of the consequences of
DAMP signaling on muscle inflammation and on muscle
regeneration is the key to promote tissue repair and healing.
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